- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02394249
SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance (SIT LESS 3)
Background of the study:
A sedentary lifestyle and obesity are well known risk factors of type 2 diabetes. The major focus of current guidelines for type 2 diabetes prevention is on energy balance. Physical activity guidelines recommend at least 30 minutes/day of moderate to vigorous physical activity (MVPA). However, no advice is given how the other 23.5 hours of the day should be spent. Several recent epidemiologic studies suggest that excessive sitting, independent of moderate to vigorous physical activity, has detrimental health effects. Another possibility to sit less is by increasing low intensity physical activities as slowly walking and standing. A recent published study of Duvivier and colleagues suggests that sitting less and replacing it by slowly walking and standing has a better effect on insulin action and cardiovascular risk factors than the combination of one hour MVPA per day and sitting the rest of the day in healthy subjects (Duvivier et al. PLOS ONE 2013). Until now this research is not performed in subjects with overweight/obesity.
Objective of the study:
To assess the effect of low intensity physical activity on plasma insulin levels, cognition and mood in subjects with overweight/obesity
Study population:
21 subjects between 40-80 years old with overweight/obesity
Intervention:
2 activity regimes of 4 days: a sitting regime and a "sit less" regime
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Maastricht, Holanda, 6200MD
- Human Movement Science, Maastricht University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Signed informed consent
- Men and postmenopausal women: 40-80 years old
- BMI: 25.0 - 35.0 kg/m2
- Maximum 2.5 hours of MVPA per week (during last 3 months)
- Having a general practitioner
- Agreeing to be informed about medically relevant personal test-results by a physician
- Accessible veins on arms as determined by examination at screening
Exclusion Criteria:
- Reported participation in another biomedical trial which may have an effect on insulin sensitivity one month before the pre-study examination or during the study
- Blood donation in the past three months
- Reported participation in night shift work 2 weeks prior to pre-study investigation or during the study. Night work is defined as working between midnight and 6.00 AM.
- Consumption of >14 (women) or > 21 (men) alcoholic units per week
- Reported dietary habits: medically prescribed diet, slimming diet;
- Reported weight loss (>2kg) in the last three months prior to the screening;
- Not being able to execute at least three (out of four) cognition tests in the training session
- Not being able to execute the sit less try-out day
- Being an employee of Unilever or the collaborating research departments in Maastricht University Medical Centre
- Experimental drug use (during the last 3 months)
- Use of insulin, oral blood glucose lowering medication (metformin and/or SU-derivatives and/or DPP-IV inhibitors), corticosteroids or vitamin K antagonists in the last 3 months
- Fasting plasma glucose level > 6.9 mmol/L
- Medical conditions which make participation in the study not responsible which will be decided by a medical doctor during screening
- Other clinically relevant abnormalities in clinical chemistry at screening (to be judged by a medical doctor)
- Mental or physical disability which interferes with physical activity
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Sitting regime
The subjects will follow the sitting regime during four days.
Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
|
Information already included in arm descriptions
|
Experimental: Sit Less regime
Subjects will follow the sit less regime during four days.
Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping.
The walking and standing will be done in a minimum of eight bouts with a time interval of >1 hour.
The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
|
Information already included in arm descriptions
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Plasma insulin levels (measured as area under the curve during an oral glucose tolerance test)
Prazo: one day after each regime
|
To assess the effect of low intensity physical activity (LIPA) on plasma insulin levels (as measured as area under the curve during an oral glucose tolerance test)
|
one day after each regime
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Insulin sensitivity (measured as Matsuda combined insulin sensitivity index during an oral glucose tolerance test)
Prazo: one day after each regime
|
To assess the effect of LIPA on insulin sensitivity
|
one day after each regime
|
Plasma C-peptide
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma C-peptide
|
one day after each regime
|
Plasma glucose levels
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma glucose levels
|
one day after each regime
|
Plasma triglycerides
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma triglycerides
|
one day after each regime
|
Plasma total cholesterol
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma total cholesterol
|
one day after each regime
|
Plasma non-HDL cholesterol
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma non-HDL cholesterol
|
one day after each regime
|
Plasma HDL cholesterol
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma HDL cholesterol
|
one day after each regime
|
Plasma LDL cholesterol
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma LDL cholesterol
|
one day after each regime
|
Plasma free fatty acids
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma free fatty acids
|
one day after each regime
|
Plasma apolipoprotein B
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma apolipoprotein B
|
one day after each regime
|
Plasma apolipoprotein A
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma apolipoprotein A
|
one day after each regime
|
Mood (measured by the Affect Grid mood scale)
Prazo: 2 days: last day of each regime and one day after each regime
|
To assess the effect of LIPA on mood
|
2 days: last day of each regime and one day after each regime
|
Attention (measured by the Attention Network Task)
Prazo: one day after each regime before and after the oral glucose tolerance test
|
To assess the effect of LIPA on attention
|
one day after each regime before and after the oral glucose tolerance test
|
Executive Function (measured by the Trail Making Test)
Prazo: one day after each regime before and after the oral glucose tolerance test
|
To assess the effect of LIPA on executive function
|
one day after each regime before and after the oral glucose tolerance test
|
Memory (measured by the Rey Auditory Verbal Learning Task)
Prazo: one day after each regime before and after the oral glucose tolerance test
|
To assess the effect of LIPA on memory
|
one day after each regime before and after the oral glucose tolerance test
|
Quality of life (measured by the Gill 32-item questionnaire)
Prazo: last day of each regime
|
To assess the effect of LIPA on quality of life
|
last day of each regime
|
Sleep (measured by the 10-item Pittsburgh Sleep Quality Index)
Prazo: last day of each regime
|
To assess the effect of LIPA on sleep
|
last day of each regime
|
Plasma C-reactive protein
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma C-reactive protein
|
one day after each regime
|
Plasma interleukin 1
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma interleukin 1
|
one day after each regime
|
Plasma interleukin 6
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma interleukin 6
|
one day after each regime
|
Plasma TNF-alpha
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma TNF-alpha
|
one day after each regime
|
Plasma interferon gamma
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma interferon gamma
|
one day after each regime
|
Plasma ICAM-1
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma ICAM-1
|
one day after each regime
|
Plasma VCAM
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma VCAM
|
one day after each regime
|
Plasma serum amyloid A (SAA)
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma SAA
|
one day after each regime
|
Plasma E-selectine
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma E-selectine
|
one day after each regime
|
Plasma von Willebrand factor (vWF)
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma vWF
|
one day after each regime
|
Plasma PAI-1
Prazo: one day after each regime
|
To assess the effect of LIPA on plasma PAI-1
|
one day after each regime
|
To explore the association between plasma glucose, plasma insulin, insulin sensitivity and mood, cognitive performance, quality of life and sleep
Prazo: one day after each regime
|
one day after each regime
|
|
Blood pressure
Prazo: one day after each regime
|
one day after each regime
|
|
Heart rate
Prazo: one day after each regime
|
one day after each regime
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Hans H Savelberg, PhD, Maastricht University Hospital
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 143046
- NL50688.068.14 (Identificador de registro: Medical Ethical Committee Maastricht University Hospital / University of Maastricht)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Physical activity regime
-
Saglik Bilimleri UniversitesiAinda não está recrutando
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); University of Rochester; University of Massachusetts...ConcluídoCâncer de mama | Sobrevivente do Câncer de Mama | Rastreadores de condicionamento físicoEstados Unidos
-
Centre Hospitalier Universitaire, AmiensConcluído
-
St. Joseph's Healthcare HamiltonHamilton Academic Health Sciences OrganizationConcluídoCâncer de Pulmão de Células Não PequenasCanadá
-
Hangzhou Normal UniversityConcluídoEstado Minimamente Consciente | Estado vegetativoChina
-
Universiteit AntwerpenUniversity Hospital, Antwerp; Cliniques universitaires Saint-Luc- Université...RecrutamentoHemofilia A | Hemofilia BBélgica